Bioventus Inc (BVS)
Oxford Ledge is still expanding full research coverage of BVS. Fundamentals and analysis (and, signed in, a delayed quote) are available in the app; the SEC-sourced material below is what we currently have indexed here.
SEC filings
- 8-K Shareholder vote results 2026-06-04
- 8-K Regulation FD disclosure 2026-05-21
- 10-Q Quarterly financial report (unaudited) 2026-05-06
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-06
- DEF 14A Proxy statement for shareholder vote 2026-04-22
Source: SEC EDGAR.
Annual results
5 years of annual figures for BVS, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $568.1M | $22.7M | $0.33 |
| 2024 | $573.3M | -$36.1M | -$0.56 |
| 2023 | $512.3M | -$156.2M | -$2.49 |
| 2022 | $512.1M | -$158.7M | -$2.59 |
| 2021 | $430.9M | $19.4M | -$0.15 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for BVS. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open BVS in Oxford Ledge — fundamentals, filings, and analysis in the app.
- Browse the stock directory
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Fundamentals are available in the app.